Monomeric C-Reactive Protein in Serum With Markedly Elevated CRP Levels Shares Common Calcium-Dependent Ligand Binding Properties With an in vitro Dissociated Form of C-Reactive Protein by Williams, RD et al.
ORIGINAL RESEARCH
published: 04 February 2020
doi: 10.3389/fimmu.2020.00115
Frontiers in Immunology | www.frontiersin.org 1 February 2020 | Volume 11 | Article 115
Edited by:
Janos G. Filep,
Université de Montréal, Canada
Reviewed by:
Karlheinz Peter,
Baker Heart and Diabetes
Institute, Australia
Yi Wu,
Xi’an Jiaotong University
(XJTU), China
*Correspondence:
Annette K. Shrive
a.k.shrive@keele.ac.uk
†Present address:
Robert D. Williams,
Birmingham Heartlands Hospital,
Birmingham, United Kingdom
Specialty section:
This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology
Received: 08 November 2019
Accepted: 16 January 2020
Published: 04 February 2020
Citation:
Williams RD, Moran JA, Fryer AA,
Littlejohn JR, Williams HM,
Greenhough TJ and Shrive AK (2020)
Monomeric C-Reactive Protein in
Serum With Markedly Elevated CRP
Levels Shares Common
Calcium-Dependent Ligand Binding
Properties With an in vitro Dissociated
Form of C-Reactive Protein.
Front. Immunol. 11:115.
doi: 10.3389/fimmu.2020.00115
Monomeric C-Reactive Protein in
Serum With Markedly Elevated CRP
Levels Shares Common
Calcium-Dependent Ligand Binding
Properties With an in vitro
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Protein
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Harry M. Williams 1, Trevor J. Greenhough 1 and Annette K. Shrive 1*
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A monomeric form of C-reactive protein (CRP) which precipitates with cell wall
pneumococcal C polysaccharide (CWPS) and retains the ability to reversibly bind
to its ligand phosphocholine has been produced through urea-induced dissociation
at an optimized concentration of 3M urea over a 10 weeks period. Dissociated
samples were purified via size exclusion chromatography and characterized by western
blot, phosphocholine affinity chromatography and CWPS precipitation. Human serum
samples from patients with raised CRP levels (>100 mg/L as determined by the
clinical laboratory assay) were purified by affinity and size exclusion chromatography and
analyzed (n = 40) to determine whether circulating monomeric CRP could be detected
ex vivo. All 40 samples tested positive for pentameric CRP via western blot and enzyme
linked immunosorbent assay (ELISA) analysis. Monomeric C-reactive protein was also
identified in all 40 patient samples tested, with an average level recorded of 1.03 mg/L
(SE = ±0.11). Both the in vitro monomeric C-reactive protein and the human serum
monomeric protein displayed a molecular weight of approximately 23 kDa, both were
recognized by the same anti-CRP monoclonal antibody and both reversibly bound to
phosphocholine in a calcium-dependent manner. In common with native pentameric
CRP, the in vitro mCRP precipitated with CWPS. These overlapping characteristics
suggest that a physiologically relevant, near-native monomeric CRP, which retains the
structure and binding properties of native CRP subunits, has been produced through in
vitro dissociation of pentameric CRP and also isolated from serumwithmarkedly elevated
CRP levels. This provides a clear route toward the in-depth study of the structure and
function of physiological monomeric CRP.
Keywords: monomeric C-reactive protein, serum C-reactive protein, dissociated C-reactive protein, calcium-
dependent ligand binding, phosphocholine, C-polysaccharide, pentraxin, innate immunity
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INTRODUCTION
C-reactive protein (CRP) belongs to the family of proteins
known as the pentraxins, which have been highly conserved
throughout evolution and can be identified in species ranging
from mammals and fish to the primitive Atlantic horseshoe crab,
Limulus polyphemus (1). The human form of CRP displays a
ring structure of five non-covalently bound subunits around
a central pore, with each subunit containing 206 amino acids
folded into two antiparallel β-sheets with a flattened jellyroll
topology (2). Two calcium ions are contained within each
promoter, forming the site for the binding of ligands such
as phosphocholine (PCho) expressed on the surface structures
of pathogens and dead or damaged cell membranes (2, 3).
The primary role of CRP within the human body is believed
to be the initiation of the innate immune response via the
classical complement pathway, cytokine induced inflammation
and interactions with antibodies. However, more complex roles
for CRP have been described, including immune exacerbation,
regulation and suppression (4–7).
In normal, healthy individuals, baseline levels of CRP
range from 1 to 5 mg/L (8). During infection, inflammation
or tissue damage, CRP levels will rise acutely to elicit a
sufficient immune response over a 24–72 h period. Due to
this rapid increase in serum levels of CRP, it is routinely
measured as a clinical biomarker for infection or inflammation
in the healthcare setting. Over recent years, evidence has
emerged linking CRP to the development and progression
of chronic, auto-inflammatory diseases such as cardiovascular
disease (9, 10). It has been hypothesized that CRP exerts
an alternative, pro-inflammatory role in disease development,
with in vitro studies demonstrating up-regulation of cell
adhesion molecules, activation of endothelial cells, deposition
within atherosclerotic lesions and the increased production
of inflammatory cytokines; all common features found in the
pathophysiology of cardiovascular disease (8, 11–15). This
evidence has led to the development of a high sensitivity CRP
assay which can accurately measure CRP levels <3 mg/L and
assess an individual’s risk of developing cardiovascular disease
(9, 10).
Although human pentameric CRP (pCRP) is extremely stable
under physiological conditions, there is increasing evidence
which suggests a biological role for a monomeric form of CRP,
commonly denoted mCRP (16–19). A wide variety of in vitro
and ex vivo monomeric CRP (mCRP) conformers have been
reported, ranging from the in vitro denatured mCRP produced
by high concentrations of urea (up to 8M) (20) through reduced
membrane bound mCRP (21) to the hybrid mCRP with near
native structure (22). Monoclonal antibodies for the various
Abbreviations: CRP, human C-reactive protein; pCRP, pentameric human
C-reactive protein; mCRP, monomeric human C-reactive protein; BSA,
bovine serum albumin; PBS, phosphate buffered saline; TMB, 3, 3′, 5, 5′,
tetramethylbenzidine; APC, p-aminophenyl phosphoryl choline; FPLC, Fast
Protein Liquid Chromatography; CWPS, Streptococcus pneumoniae cell wall
C-polysaccharide; NRES, National Health Service Research Ethics Service; EDTA,
ethylenediaminetetraacetic acid; ELISA, enzyme linked immunosorbent assay;
tris, tris(hydroxymethyl)aminomethane; PCho, phosphocholine.
conformers have been generated, including those targeting neo-
epitopes revealed by pCRP subunit dissociation, and used to
identify monomeric forms as distinct from pCRP (23–25). The
urea dissociated mCRP of Potempa et al. (20) remains very much
the prototypical mCRP, being used in a wide variety of studies
for over 30 years. This mCRP displays a decrease in solubility
(being insoluble in calcium concentrations as low as 0.05mM)
and isoelectric point and a loss of calcium-dependent binding
to the prototypical CRP ligand C-polysaccharide (20). This
monomer could not be re-associated back into its pentameric
form, the dissociation being accompanied by significant changes
in both structure and function (26). On the basis of reduction
of the intrachain disulphide in this mCRP, but not in pCRP,
by reducing agents such as dithiothreitol, several reports have
shown discrimination between pentameric and monomeric CRP
(21, 27, 28).
Several models suggesting a physiological mechanism for the
formation of mCRP have been postulated within the literature.
The most widely accepted involves dissociation through calcium-
dependent binding of pCRP to cell membranes (17, 18, 25,
27–32) although a clear picture is yet to emerge of the
nature and fate of the resulting mCRP conformer. Binding to
microvesicles has been proposed to lead to pCRP structural
changes that allow binding of C1q and hence complement
activation (27). In addition, increasing experimental evidence
within the literature suggests a pro-inflammatory role for mCRP
(33) and a link between mCRP and the progression of certain
auto-inflammatory diseases within the body. Similarly to that
described previously for pCRP, mCRP displays an ability to
stimulate cytokine production and up-regulate the production of
adhesionmolecules as well as induce thrombus growth formation
and alter fibrin properties and tissue factor expression (18,
34). It has been hypothesized that circulating micro-particles,
generated from lipid membranes, can not only induce pCRP
dissociation, but also act as a mode of transport around the body
to sites of intensified inflammation (30). The failure of standard
clinical CRP tests, employed in a large proportion of healthcare
laboratories, to detect mCRP that is bound to circulating micro-
particles has also been highlighted (35).
More recently, the development of ELISA methods which
can quantify mCRP in clinical serum and tissue samples
down to 1 ng/ml have been reported (24, 36). Zhang et al.
(36) demonstrated a sandwich ELISA that detected mCRP
in patients with skin-related autoimmune disorders, with a
statistical difference in mCRP levels when compared to the
control group, even when native, pentameric samples showed
no such difference (35). Levels of serum mCRP reported by
Zhang et al. (36) were in the ng/ml range, as were those
reported by Wang et al. (24) who employed a monoclonal
antibody based on the C-terminal octapeptide of CRP, proposed
to be exposed on pCRP dissociation by treatment with 8M
urea, in a study of mCRP levels in acute myocardial infarction
(AMI). The antibody was shown to recognize mCRP from
denatured pCRP, but not pCRP itself. This study of patients
(n = 101) who had recently suffered with an AMI reported
an average recorded mCRP serum level of 0.021 mg/L (24),
with six patients out of 42 with raised levels of pCRP
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(3–285 mg/L) displaying detectable mCRP levels of 0.0057
mg/L−0.1227 mg/L.
Our aim was to generate, and find in serum with markedly
elevated CRP levels, a near native mCRP that retains as far
as possible the structure and binding of the monomer in the
pentameric molecule. We describe the production, purification
and characterization of in vitro mCRP, produced under milder
dissociation conditions than those usually employed, alongside
the analysis of human serum samples from patients exhibiting
raised CRP levels (>100 mg/L) by clinical assay. This analysis
reveals an ex vivo form of mCRP in all patient samples analyzed.
Both forms of mCRP were recognized by the same anti-CRP
monoclonal antibody, both were soluble in tris buffered saline
with 5–10mM CaCl2, and both reversibly bound to PCho in a
calcium-dependent manner.
MATERIALS AND METHODS
Standard buffers used were as follows: buffer A: (storage buffer)
20mM tris(hydroxymethyl) aminomethane (tris), 280mMNaCl,
5mM CaCl2, 0.01% sodium azide, pH 7.4; buffer B: (elution
buffer) 50mM tris, 150mMNaCl, pH 7.2; buffer C: (equilibration
buffer) 10mM CaCl2, 50mM tris pH 7.4, 150mM NaCl,
0.01% sodium azide; buffer D: (chelating buffer) 10mM
ethylenediaminetetraacetic acid (EDTA), 50mM tris pH 7.4,
150mM NaCl, 0.01% sodium azide.
ELISA Protocol
The general procedures for ELISA were as follows: All ELISA
analysis was carried out on a sterile, 96-well plate (Costar). 50 µl
of each sample was added to each well. Plates were blocked with
3% bovine serum albumin (BSA) and washed with phosphate
buffered saline (PBS)-Tween (Sigma). The primary antibody
used was a monoclonal anti-C-reactive protein antibody (CRP-8,
Sigma) produced in amouse; the secondary antibody was an anti-
mouse IgG (whole molecule)–peroxidase antibody produced in
rabbit (Sigma). Both were used at 1:40,000 dilution. Positive and
negative controls were included in analysis and all samples were
tested in triplicate. The developing substrate used was 3, 3′, 5,
5′, tetramethylbenzidine (TMB) liquid substrate (Sigma). ELISA
plates were left to develop for 10min prior to addition of 2M
sulfuric acid. Plates were read at 450 nm on a BioTek EL800 plate
reader using Gen5 software.
Production of in vitro Monomeric
C-Reactive Protein
Native pentameric human CRP (pCRP) was purchased from
Scripps in storage buffer (buffer A). Dissociation was achieved
through the addition of pCRP to a range of dissociation buffers
(20mM tris, 280mM NaCl, 1mM EDTA, and 2, 2.5, 3, and 4M
urea), followed by storage at 4◦C for periods of up to 12 weeks.
Phosphocholine (PCho) Affinity
Chromatography
Immobilized p-aminophenyl phosphoryl choline (APC) was
purchased from Fisher Scientific in the form of a gel, cross-
linked with 6% beaded agarose. The binding capacity of the APC
was >3mg of CRP per 1ml of gel. All affinity chromatography
experiments for both in vitro and ex vivo CRP were run using the
Biologic LP Chromatography System (BioRad) with a flow rate of
0.5ml/min throughout. The absorbance wasmeasured at 280 nm.
Prior to samples being run through the column, the column
was equilibrated with 20 column volumes of equilibration buffer
(buffer C) and the UV absorbance baseline reading was then
blanked to a value of 0 absorbance units (Au) prior to application
of the sample. Once the entire sample had been applied, the
column was re-equilibrated with 5 column volumes of buffer C
followed by elution with the chelating buffer (buffer D) until the
UV absorbance reading had returned to its baseline value of 0 Au.
Purification of in vitro Monomeric
C-Reactive Protein (mCRP)
mCRP and pCRP in the urea dissociated samples were separated
and purified using the AKTA explorer 100 Fast Protein
Liquid Chromatography (FPLC) system (GE Healthcare) with
a HiLoad 16/60 Superdex 200 pg column. Calibration was
performed using a Gel Filtration Calibration Kit (GEHealthcare),
with the included molecular weight markers ferritin, aldolase,
conalbumin, ovalbumin, and ribonuclease (elution buffer: buffer
B). The void volumewas determined using Blue Dextran (Sigma).
Samples were injected onto the column via a 2ml sample
injection loop and elution was monitored by UV absorbance at
280 nm at a flow rate of 0.5 ml/min. Samples were eluted off and
collected in 5ml fractions in the storage buffer A.
SDS PAGE and Western Blots of Purified
pCRP and in vitro mCRP Samples
Both purified dissociated CRP samples and CRP purified from
human serum were confirmed to contain CRP through sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE)
and western blot analysis. Samples were run under non-reducing
conditions on a 12.5% resolving and 4% stacking gel. All reagents
were purchased from Sigma. SDS PAGE was run in a BioRad
mini-Protein II cell at 200V for approximately 45–50min.
All samples were run with positive and negative controls and
molecular weight markers.
Western blot analysis was performed using the Mini Trans-
Blot Electrophoretic Transfer Cell (BioRad), using nitrocellulose
blotting paper or Polyvinylidene difluoride (PVDF) membrane.
The transfer was run at 350mA for 1 h at 4◦C. Membranes
were blocked with Marvel dried milk powder and washed with
BLOTTO (Marvel dried milk, Triton-X 100 or Tween-20, and
tris-buffered saline). The primary antibody, amonoclonal anti-C-
reactive protein antibody (CRP-8, Sigma) produced in a mouse,
was used at a 1:1,000 dilution except for the mCRP purified
from human serum (1:400) and for the non-dissociated pCRP
following treatment with urea (1:200). The secondary antibody,
an anti-mouse IgG (whole molecule)–peroxidase antibody
produced in rabbit (Sigma), was used at a 1:40,000 dilution
except for the non-dissociated pCRP following treatment with
urea (1:2,000). Clarity Western Enzyme Chemiluminescence
substrate (BioRad) or Thermo ScientificTM SuperSignalTM West
Pico Chemiluminescent Substrate diluted x4 was used to detect
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protein bands which were visualized using a CCD digital image
detector. Exposure time was approximately 30–60 min.
Binding of in vitro mCRP to
Phosphocholine
The calcium-dependent binding to PCho of the size exclusion
purified mCRP from the 3M urea dissociation was assessed
using PCho affinity chromatography as described above. Protein
samples were prepared by diluting 500 µl (250 µg) of the mCRP
in 5ml of buffer C. Larger volumes of samples were used to
prevent air bubbles entering the columnwhilst applying a sample.
Precipitation Studies With Streptococcus
pneumoniae Cell Wall Polysaccharide
ELISA Calibration
50 µl of calcium buffer (buffer A) was added to columns 1–12,
rows A–F of the ELISA plate. 50 µl (3.0 µg in 50 µl, 60 mg/L) of
pCRP (Scripps) was added to column 1, rows A–C, andmCRP (in
vitro, purified following the 3M dissociation) to rows D–F. Serial
dilution through to column 11, rows A–F was carried out leaving
buffer A in column 12 rows A–F (negative control).
CRP/CWPS Precipitation
Native pCRP (Scripps) alongside mCRP (dissociated with 3M
urea and purified by size exclusion), were incubated with varying
amounts of Streptococcus pneumoniae cell wall C-polysaccharide
(CWPS; Oxford Biosystems). CWPS quantities used were 0.1, 0.5,
1, 10, 20, 50, 100, 200, 300 µg. Both CRP samples contained 20
µg in 400 µl buffer A. All samples were incubated at 37◦C for 1 h
whilst being gently agitated. The samples were then centrifuged at
6,500× g for 15min to pellet the precipitate and the supernatant
from each sample was transferred to separate tubes. Precipitation
levels were calculated based on the remaining concentration
of protein within the supernatant via ELISA following the
general procedures outlined above. CRP concentrations were
determined using the calibration line equations and the total level
of precipitation was calculated by subtracting the total amount
of CRP remaining in solution post CWPS incubation from the
initial amount (20 µg).
Protein Concentration and Quantification
Eluted protein samples were stored for use at 4◦C in the
various elution buffers following concentration using a Vivaspin
Centrifugal Concentrator (Fisher Scientific), 10 kDa molecular
weight cut off. The concentrator was initially primed with
deionised water and spun at 1,000 x g, 4◦C for 10min.
The protein sample was then spun at 1,000 × g, 4◦C for
15min or until the desired concentration had been achieved.
The protein content of the CRP samples was determined
from absorbance at UV 280 nm. The extinction coefficient was
calculated from the CRP sequence as 1.7 (Expasy, http://web.
expasy.org/protparam/).
Ethical Application and Research Study
Design
Ethical approval for the human serum samples pilot study was
granted by UK National Health Service Research Ethics Service
(NRES) Committee South Central—Oxford B (REC reference:
15/SC/0179). A total of 40 inpatients at the University Hospitals
of NorthMidlands (UHNM), identified only by sample numbers,
were recruited who were over the age of 18, were able to give
informed consent, were due to undergo a routine blood test
and who had a serum CRP level >100 mg/L as measured by
immunoturbidimetry on the Siemens Advia 2400 assay (Siemens
Healthcare Diagnostics Limited, Frimley, UK). All aspects of our
study were compliant with the regulatory terms and conditions
set out by the NRES committee and Keele University local
ethics committee.
Human Serum Sample Collection
Whole human blood was collected into BD Vacutainer SST gel
tubes without anticoagulant. Sample tubes were left for 30min to
clot and centrifuged at 3,500 g for 7min to separate the serum.
Serum samples were stored at 4◦C.
Purification of CRP From the Human
Serum Samples
CRP was purified from human serum with markedly elevated
CRP levels (>100 mg/L), as determined by the routinely used
clinical assay, via PCho affinity chromatography as described
above. Serum sample volumes were 900 µl. Eluted samples were
then purified via size exclusion chromatography as described
for the in vitro analysis to separate out potential CRP isoforms.
Briefly, samples were applied to the column via a 2ml sample
injection loop. Sample elution using buffer A was monitored by
UV absorbance at 280 nm at a flow rate of 0.5 ml/min. pCRP and
mCRP elution times were calculated prior to purification based
on the in vitro studies.
ELISA Analysis of CRP From Human Serum
Samples
Following elution from the size exclusion chromatography
column, the purified pCRP and mCRP from the human serum
samples were also subject to ELISA analysis following the general
procedures outlined above. The purified human serum pCRP
and mCRP fractions were diluted in buffer A 1:100 and 1:10,
respectively, prior to analysis. For the calibration, 50 µl of
calcium buffer (buffer A) was added to columns 1–8, rows A–
B of the ELISA plate. 50 µl of either native pCRP (Scripps) or
mCRP (in vitro, purified following the 3M urea dissociation) was
added to column 1, rows A–B (0.165 µg, 0.0033 mg/ml). Serial
dilution through to column 7, rows A–B was carried out leaving
only calcium buffer in column 8, rows A–B (negative control).
Experimental Procedures for the Human
Serum Samples Applied to Commercially
Sourced CRP
The general methods for affinity and size exclusion
chromatography, and for ELISA, are given elsewhere. Specifics
for this experimental procedure were as follows: A total of
3.0mg (1.2ml at 2.5 mg/ml) CRP (Binding Site) was applied
to the PCho affinity column. EDTA eluted 3ml CRP fractions
were collected and concentrated using a Vivaspin Turbo 15
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(10 kDa MWCO) at 4◦C, 2,100 rpm for 10min. Following
recalibration of the size exclusion column (necessary due to
a change of column) using molecular weight standards CRP
(115 kDa), conalbumin (75 kDa), ovalbumin (43 kDa), carbonic
anhydrase (29 kDa, ribonuclease (13.7 kDa), and aprotinin (6.5
kDa), size exclusion FPLC of this PCho purified CRP was carried
out at a flow rate of 0.5 ml/min. Two size exclusion runs were
carried out, the first loading 500 µg of the CRP, in excess of
the CRP in the serum sample with the largest clinically assayed
CRP level, the second loading 100 µg. The fractions spanning
the mCRP elution volume indicated by the calibration were
collected (six 5ml fractions in each case), diluted 1:100 and 1:50
in calcium buffer and subjected to ELISA (primary antibody
CRP-8) in triplicate for all fractions. Two ELISA plates were
completed, one for the 500 µg size exclusion chromatography
(SEC) fractions, the other for the fractions from the 100 µg
SEC experiment. Both included a calibration in triplicate
using serial dilution of 6 ng of mCRP (3M urea dissociated)
along with positive (4 ng mCRP) and negative (calcium buffer,
buffer A) controls.
RESULTS
Production and Purification of in vitro
Monomeric C-Reactive Protein
Size exclusion chromatography was used to assess the level of
dissociation of pentameric CRP into monomeric CRP in the
presence of 1mM EDTA under a range of urea concentrations,
each over a period of several weeks, and to purify out both
pCRP and mCRP from the sample. This resulted in the
selection of 2–4M urea over a period of 10 weeks. For the
calibration, the void volume was calculated to be 46.79ml
and the column volume 120.6ml. Elution volumes for the
molecular weight standards are given in Table S1 and the
calibration graph in Figure S1. The elution traces are shown
in Figure 1 and the elution volumes and calculated molecular
weights in Table 1. There is no evidence in the elution traces of
intermediate CRP aggregations comprising 2, 3, or 4 subunits.
5ml fractions were collected throughout the elutions, the two
fractions associated with each peak, for example 75–80ml,
80–85ml for pCRP, 90–95ml, 95–100ml for mCRP for the
3M dissociation, being collected, pooled, and concentrated in
the elution buffer for further characterization. Measurement
of protein concentration (absorption at UV 280 nm) for the
concentrated pCRP and mCRP samples suggested losses of
up to 50% with respect to the starting pCRP. Losses do vary
significantly, with a direct correlation between the amounts
of CRP, and there appears to be a “baseline” loss, particularly
during the concentration step, irrespective of the quantity.
This clearly has a much greater effect for small quantities.
For quantities of CRP in the mg range yields of up to
90% following size exclusion and concentration are achievable,
while for small quantities, in the µg range, losses of up
to 50% are common.
The 3M urea dissociation (Figure 1C) clearly maximizes both
mCRP yield and pCRP to mCRP conversion and was therefore
used in subsequent studies. No evidence of dissociation was
observed in the presence of calcium (5mM) (results not shown).
Western Blots of the Purified in vitro pCRP
Dissociation Products
Western blots (Figure 2) of the size exclusion chromatography
eluted monomeric and un-dissociated pentameric CRP fractions
(Figure 1) confirmed the ability of the proteins to still be
recognized by the anti-CRP antibody.
Binding of Purified in vitro Monomeric CRP
to Phosphocholine
The 3M urea dissociated mCRP purified by size-exclusion
was applied to a PCho affinity column followed by elution
with EDTA chelating buffer (buffer D) (Figure 2). The pooled
mCRP fractions were concentrated and subjected to western blot
analysis (Figure 2) confirming the ability of the protein to still be
recognized by the anti-CRP antibody. Measurement of protein
concentration (absorption at UV 280 nm) for the concentrated
mCRP sample suggested losses of up to 70% with respect to the
starting mCRP.
Precipitation Studies With Streptococcus
pneumoniae Cell Wall Polysaccharide
Precipitation of mCRP and pCRP with CWPS was carried out.
The ELISA calibration data and graphs for pCRP and mCRP are
given in Tables S2, S3, Figures S2, S3. The levels of precipitation
for both native pCRP and in vitro produced, size exclusion
purified mCRP (3M urea dissociated) when incubated with
varying amounts of CWPS are shown in Figure 3.
Pentameric CRP displays the classic precipitation curve (37)
with little precipitation with CWPS at either end of the curve
where protein or ligand is in significant excess. Approximately
2 µg of pCRP precipitates out of solution when incubated with
0.1 µg of CWPS, while 7 µg of pCRP precipitates out of solution
when incubated with 300 µg of CWPS. Maximum precipitation
(17 µg out of a total of 20 µg of pCRP) occurs where protein and
CWPS quantities are the same (20 µg). Precipitation by mCRP
maintains a general level of approximately 5–7 µg irrespective of
the amount of CWPS, peaking at just over 7 µg, when mCRP
is incubated with 50 µg of CWPS, although this peak level is
still markedly lower than that for pCRP with 50 µg of CWPS
(approximately 15 µg).
Purification of CRP From Human Serum
Samples
Serum samples from 40 patients with elevated CRP levels (>100
mg/L by clinical assay) were purified individually by PCho
affinity chromatography (Figure S4). Further purification and
characterization then followed the procedures employed for the
in vitromCRP. All affinity purified samples were subjected to size
exclusion chromatography (Figure 4). The major peak eluted at
79.01ml (110 kDa; Figure S1; pCRP]. Although no mCRP peak,
expected at 95ml, was observed in any of the purified samples
(Figure 4), fractions 90–95 and 95–100ml (see Table 1, Figure 1)
were pooled for further analysis.
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FIGURE 1 | Generation of monomeric CRP. Size exclusion chromatography traces for the urea dissociation experiments with 1mM EDTA. In each case Peak 1
represents eluted pentameric CRP and peak 2 represents eluted monomeric CRP. (A) 2M urea (B) 2.5M urea (C) 3M urea (D) 4M urea—peak 3 determined as not
significant based on calculated molecular weight.
TABLE 1 | Size exclusion column elution volumes and calculated molecular weights following pCRP dissociation via varying concentrations of urea.
2M urea 2.5M urea 3M urea 4M urea
Elution
vol (ml)
MW
(kDa)
Elution
vol (ml)
MW
(kDa)
Elution
vol (ml)
MW
(kDa)
Elution
vol (ml)
MW
(kDa)
pCRP 79.02 108 79.09 109 79.60 103 79.27 107
mCRP 95.65 21.3 95.68 21.2 94.97 22.0 94.90 22.0
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FIGURE 2 | Characterization of in vitro monomeric CRP. (A) Western blots (non-reducing 12.5% SDS) of the (a) pentameric and (b) monomeric fractions of CRP from
the size exclusion chromatography analysis following dissociation with urea. (a) Lane 1 (0.1 µg) and lane 2 (1 µg) contain the pentameric fraction separated from the
3M urea dissociated sample with control pCRP in lane 3. (b) Lanes 1, 3, 5, 7 contain the monomeric fraction separated from the 2, 2.5, 3, and 4M urea dissociated
samples, respectively. Lanes 2, 4, 6, 8 contain buffer. Lane 9: 3M urea dissociated mCRP (Lane 5) subsequently eluted from the PC affinity column by EDTA (b). This
Lane was excised from the blot after 5min exposure, the remaining Lanes 1–8 being exposed for a further 40min. Lane 10 Molecular weight markers (Biorad
precision plus unstained) excised before blotting and stained with Coomassie brilliant blue. The dashed line indicates 23 kDa. (B) PCho affinity chromatography of the
size-exclusion purified, in vitro produced mCRP (from 3M urea, Lane 5, Ab). The major peak represents elution of mCRP by the calcium chelator EDTA. Time
represents elapsed time after the mCRP sample was loaded. The Western blot of the PCho affinity purified mCRP is shown in Lane 9 of the blot in (Ab).
Analysis of Pentameric and Monomeric
C-Reactive Protein Within the Human
Serum Samples
Affinity chromatography followed by size exclusion purified
fractions of both pentameric and monomeric CRP were each
subject to ELISA analysis and quantification. The calibration
details are given in Table S4, Figure S5 (mCRP) and Table S5,
Figure S6 (pCRP). All CRP concentrations were adjusted to
represent the concentration in the initial serum samples. All
40 purified pCRP samples tested positive in the ELISA for
the presence of CRP (Figure 5). The lowest recorded value of
pentameric CRP for any of the samples was calculated at 2.5
mg/L, with the highest being recorded at 71.3 mg/L and a mean
value of 23.3 mg/L (SE = ±2.3). All 40 samples of the purified
monomeric form of CRP from serum also tested positive for
the presence of CRP (Figure 5) with a mean value of 1.03 mg/L
(SE = ±0.11), the highest value being 3.14 mg/L (sample 148).
There is no significant correlation between the serum mCRP
and pCRP (Figure 5) concentrations across all the samples with,
for example, the higher mCRP values being associated in equal
measure with both high and low pCRP levels (Figure S7). The
purified pentameric and monomeric CRP fractions from the size
exclusion columnwere also subject to western blot analysis. All 40
pCRP samples tested positive for CRP, a representative selection
is shown in Figure 5. For mCRP, the western blots revealed
CRP in 3 out of the 40 patient sample derived mCRP samples
(Figure 5).
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FIGURE 3 | Precipitation of pCRP (20 µg) and mCRP (3M urea, 20 µg) with
CWPS. Errors shown are ± standard deviation (n = 2).
Experimental Procedures for the Human
Serum Samples Applied to Commercially
Sourced CRP
Application to commercially sourced CRP of our experimental
procedures (PCho-affinity chromatography followed by
separation of pCRP and mCRP by SEC) for isolation of mCRP
from patient serum samples, all showing markedly elevated CRP
levels >100 mg/L by clinical assay, was carried out to confirm
that these purification procedures do not produce the mCRP
detected in patient samples. PCho affinity chromatography of the
commercially sourced CRP gave a clean, sharp peak with EDTA
elution (Figure S8A). EDTA eluted 3ml CRP fractions G9–G11
(Figure S8A) were collected and concentrated to 2ml at 1.44
mg/ml (2.88mg CRP). Application of the PCho purified CRP
to the size exclusion column (two separate runs, loading 500 µg
and 100 µg) showed the pCRP peak at the expected position of
70–71ml (Figures S8B,C) indicated by the calibration (Table S6,
Figure S9) with no discernible peak at the mCRP position
(90–91ml). ELISA analysis of the PCho+ size exclusion purified
native CRP for both the 500 µg (Tables S7, S8, Figure S10) and
100 µg (Tables S9, S10, Figure S11) size exclusion runs revealed
no detectable mCRP. Fraction E5 for the higher (500 µg) size
exclusion column loading shows a positive CRP reading of 1.25
mg/L associated with the pCRP tail (Figure 6A), while CRP
could not be identified in any fraction of either run in the region
of the mCRP elution volume. (Figure 6B).
DISCUSSION
C-reactive protein dissociation experiments using commercially
sourced pCRP and a range of urea concentrations were carried
out over a 10 week period to establish a suitable in vitro
protocol for the production of monomeric C-reactive protein.
The aim was to minimize the strength of urea whilst still
inducing a high level of dissociation over a realistic time frame.
Although the mechanism of dissociation in the presence of
urea is not clear, we believe this is the most suitable method
of those reported in the literature (20) since attempts to treat
pentameric CRP with heat or acidic conditions resulted in
FIGURE 4 | Typical size exclusion chromatography trace of one of the PCho
affinity purified human serum samples. The pCRP peak is clear while no peak
is visible for mCRP.
complete denaturation of the protein (data not shown). The
most appropriate urea concentration for the almost complete
dissociation of pentameric to monomeric CRP (>90%) was 3M
(Figure 1). Lower concentrations of urea resulted in partial or
no dissociation, while the removal of the CRP calcium ions
was shown to be crucial regardless of the urea concentration.
Dissociated samples were successfully separated into mCRP
and residual pCRP by size exclusion chromatography, western
blot analysis confirming the ability of both proteins to still be
recognized by the anti-CRP antibody.
Further characterization of the in vitro mCRP was carried
out using PCho affinity chromatography and precipitation
with CWPS. The PCho affinity chromatography mCRP peak
(Figure 2) confirms the calcium-dependent PCho-binding ability
of the in vitro produced mCRP, further verified by western blot
analysis of the eluted peak which, as expected, was positive for
CRP. Based on this experimental evidence it was concluded that
the urea dissociation experiments successfully dissociated pCRP
into its constituent subunits yielding an in vitro form of mCRP
that retained its PCho-binding ability. Precipitation studies with
CWPS (Figure 3) revealed that the in vitro mCRP produced
here also retains the ability to recognize its prototypical ligand
CWPS. However, unlike the CWPS precipitation curve observed
for pCRP, the in vitro producedmCRP does not follow the general
bell-shaped curve typical of aggregation and precipitation of a
cross-linked complex (37). The lower level of precipitation and
its increased uniformity over a range of CWPS concentrations
compared to pCRP, where each pentamer can achieve cross-
linking through multi-site CWPS attachment to one or more
CWPS, is consistent with the single PCho binding site per
monomer reducing the opportunity for aggregation, although
modification of the monomer which reduces, but does not
abrogate, CWPS binding cannot be discounted. Previous reports
using 8Murea for dissociation have described the production of a
monomeric form of CRP which displayed a decrease in solubility
[aggregating and forming precipitates at calcium concentrations
as low as 0.05mM (9)] and isoelectric point, and loss of calcium-
dependent binding to the prototypical CRP ligand CWPS (20).
This suggests that the in vitro mCRP produced here at 3M urea
differs from that previously described.
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FIGURE 5 | ELISA and western blot analysis of pentameric and monomeric CRP in the human serum samples. (A,B) ELISA analysis. All 40 samples tested positive
for both pCRP and mCRP. Scores are based on the average value minus the average control. Errors shown are ± standard deviation (n = 3). (A) Samples were
diluted 1:100 in triplicate. The average concentration of pCRP is 23.3 mg/L (SE = ±2.3). (B) Samples were diluted 1:10 in triplicate. The average concentration of
mCRP is 1.03 mg/L (SE= ± 0.11). (C,D)Western blot (non-reducing 12.5% SDS) analysis of the pentameric and monomeric human serum CRP fractions eluted from
the size exclusion column. (C) Pentameric CRP was positive for all 40 samples tested (CRP 148, 146, 124, 120, 117, 115, 110, 109, 108 in lanes 1–9, respectively,
are shown here). Control pCRP (∼23 kDa) sample in lane 10. (D) Monomeric CRP: eight of the forty serum samples (018, 021, 023, 109, 115, 148, 153, 175) are
shown with two samples (Lane 5, sample 115; Lane 6, sample 148; the two highest values in the mCRP ELISA) positive for mCRP at a molecular weight of
approximately 23 kDa. Lane 9 contains urea dissociated mCRP control at 23 kDa, this lane being excised from the gel after 2.5min with the remainder exposed for a
further 42.5min. One other sample (204, the fourth highest ELISA mCRP value) was positive for mCRP in western blots (data not shown). The mCRP from sample
012, which gave the highest pCRP ELISA reading and the third highest mCRP ELISA value, could not be visualized by western blotting.
The experimental evidence provided by the in vitro
dissociation studies, providing a monomeric CRP with MW
approximately 23 kDa which reversibly binds PCho in a calcium-
dependent manner, precipitates with CWPS and is recognized
by an anti-CRP monoclonal antibody, formed the basis for
the methodology developed for the analysis of monomeric
C-reactive protein in human serum from patients with markedly
elevated CRP levels >100 mg/L. Our aim was to carry out this
analysis independent of antibodies specific for one or more forms
of mCRP, or specific for particular mCRP epitopes, using samples
from patients with clinically recorded raised pCRP levels, >100
mg/L. Thus, PCho affinity chromatography followed by size
exclusion, complemented by western blotting and ELISA were
used for the isolation, purification, and detection of serum
monomeric CRP. The average concentration of pentameric CRP
in the patient serum samples was calculated from the ELISA data
to be 23.3 mg/L, with the minimum value calculated to be 2.5
mg/L and the maximum 71.3 mg/L (Figure 5). The difference
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FIGURE 6 | Size exclusion FPLC of PCho re-purified CRP. Elution traces are shown for both (A) 500 µg and (B) 100 µg CRP loaded onto the column. Fractions
E5–E10 and J5–J10 (5ml each) were diluted 1:100 and 1:50 in calcium buffer and subjected to ELISA (primary antibody CRP-8) in triplicate (see Tables S7–S10,
Figures S10, S11). Total CRP in mg/L averaged over the two dilutions is shown for each fraction. Fraction E5 for the higher (500 µg) loading shows a positive reading
associated with the pCRP tail, while CRP could not be identified in any other fraction or in any fraction of the 100 µg run. The two fractions within which mCRP would
elute are indicated.
between the pCRP levels determined here and those provided by
clinical assay, all of which were reported as >100 mg/L, suggests
significant losses during the purification procedure and the need
for more efficient processes for the quantification of CRP forms.
Monomeric CRP was successfully identified by ELISA in the
purified CRP of all the 40 patient serum samples (Figure 5) with
three of the four highest concentrations also being detected on
western blots. Combined with the PCho affinity chromatography
used for purification, our results demonstrate that the serum
monomeric CRP not only displays the same ability as the
dissociated in vitromCRP to reversibly bind to PCho in a calcium
dependent manner, but also is recognized by the same anti-
CRP monoclonal as both pCRP and in vitro mCRP. From the
ELISA, the mean recorded level of monomeric CRP within the
serum samples was 1.03 mg/L, with the minimum recorded
value being 0.12 mg/L and the maximum recorded value
being 3.14 mg/L. Significantly, the two highest mCRP serum
concentrations calculated from ELISA (samples 115 and samples
148; Figure 5) were detected by western blotting (Figure 5).
There is no correlation between the abundance of the two
molecular forms (Figure S7), for example of the ten highest
serum pCRP values (Figure 5) only three corresponded to one
of the ten highest mCRP values (Figure 5). These results suggest
that serum monomeric CRP levels are significantly lower than
those for pentameric CRP, with monomeric CRP levels varying
across the cohort. Despite the loss of protein in the purification
and concentration process, the PCho-binding monomeric CRP is
detectable in the serum of patients with markedly elevated CRP
levels at an order of magnitude higher levels when compared to
previously published data based on serum ELISA (24, 36). While
this may be due to the different procedures, to our inclusion of
only patients with raised CRP levels >100 mg/L, or to mCRP
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bound to microparticles evading the PCho affinity extraction (30,
35), it raises the possibility of two different forms of circulating
mCRP. As the patient samples used here all have markedly
elevated levels of CRP, no conclusions can be drawn from the data
presented here as to whether mCRP is present in normal, healthy
serum, or the nature of that mCRP if present.
In order to verify that themCRP identified here in serum is not
a product of our purification procedures, commercially sourced
native CRP was subjected to those same procedures as the serum
samples, involving PCho affinity chromatography (which would
isolate any of the calcium dependent PCho binding soluble
mCRP in addition to pCRP), concentration, size exclusion, and
ELISA using the same antibody (CRP-8). The results (Figure 6)
show that mCRP is not a product of our procedures, with no
mCRP detectable by ELISA. Our conclusion therefore is that
the calcium dependent PC binding, soluble mCRP identified and
characterized here is present at detectable levels in serum with
markedly elevated levels of CRP.
The mCRP isolated from human serum samples, in this case
where pCRP levels were clinically assayed as >100 mg/L, and
the 3M urea for 10 weeks dissociated mCRP samples share key
binding properties. Both display the ability to reversibly bind
to PCho in a calcium-dependent manner and in common with
pCRP both are recognized by the same anti-CRP monoclonal
antibody. Precipitation of the urea dissociatedmCRPwith CWPS
further suggests that both forms investigated here retain the
overall structural and functional properties of CRP monomers
within the pentameric CRP molecule. This suggests that the
mCRP detected here in serum with markedly elevated CRP levels
is similar to the membrane-bound dissociated subunit with near
native structure proposed by Lv andWang (22), Zhang et al. (36),
and Ji et al. (25) rather than the variety of reduced, denatured and
refolded mCRP reported elsewhere. It has been suggested that
a near-native membrane-bound mCRP is an intermediate step
between dissociation, following pCRP membrane attachment,
and release following conformational change (25, 27). Whether
the serum mCRP detected here is released from the cell surface
following pCRP dissociation or whether it originates elsewhere
is not clear. If it is of cell surface bound pCRP origin then this
suggests that conversion to a conformationally distinct mCRP
following dissociation is not a prerequisite for release from
the membrane.
The overlapping characteristics of the in vitro and ex vivo
mCRP reported here suggest that a physiologically relevant
monomeric CRP, which retains near native pCRP subunit
structure and function, has been produced through in vitro
dissociation of pentameric CRP using 3M urea over an extended
period. This has the potential to provide not only new routes to
quantification of both pCRP andmCRP in the clinical setting, but
also a firm basis for the in-depth study of the structure, function
and diversity of physiological CRP.
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